Welcome to our dedicated page for Apellis Pharmace news (Ticker: APLS), a resource for investors and traders seeking the latest updates and insights on Apellis Pharmace stock.
Apellis Pharmaceuticals, Inc. (APLS) is a leader in developing transformative therapies targeting the complement system, with approved treatments for geographic atrophy and rare blood disorders. This page provides investors and researchers with essential updates on the company’s progress in retinal, hematologic, and renal disease innovation.
Access timely announcements including FDA decisions, clinical trial results, and strategic partnerships that demonstrate Apellis’ commitment to advancing complement immunotherapy. Our curated news collection covers critical developments such as SYFOVRE’s commercial adoption, EMPAVELI’s clinical applications, and research collaborations expanding therapeutic pipelines.
Key updates include regulatory milestones in ophthalmology, hematology treatment expansions, and nephrology research advancements. Bookmark this page to stay informed about Apellis’ pioneering work in C3-targeted therapies and its impact on addressing diseases with limited treatment options.
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation in two major investor conferences in June 2022. The Jefferies Healthcare Conference features a fireside chat on June 9, 2022, at 4:30 p.m. ET, while the Goldman Sachs 43rd Annual Global Healthcare Conference will take place on June 15, 2022, at 9:20 a.m. PT. Both events will be available via live webcast and can be accessed from the company's website. Following the events, webcasts will be replayable for 90 days.
Apellis Pharmaceuticals (APLS) announced the submission of a New Drug Application (NDA) to the FDA for pegcetacoplan, targeting geographic atrophy (GA) secondary to age-related macular degeneration (AMD). GA affects over 5 million people worldwide, with no current approved treatments. Pegcetacoplan has shown promise in reducing GA lesion growth in Phase 3 studies, DERBY and OAKS, as well as the Phase 2 FILLY study. The FDA is expected to respond to the NDA by August 2022.
Apellis Pharmaceuticals (Nasdaq: APLS) announced that it will present seven abstracts at the European Hematology Association (EHA) Congress from June 9-12 in Vienna, focusing on EMPAVELI® (pegcetacoplan) for treating paroxysmal nocturnal hemoglobinuria (PNH).
The highlights include an oral presentation on quality of life improvements and several posters showcasing efficacy and safety data.
EMPAVELI is gaining traction as a potential new standard of care for PNH, with ongoing investigations for additional indications.
Apellis Pharmaceuticals (APLS) announced the approval of equity inducement awards to four new employees on May 2, 2022, under its 2022 Inducement Stock Incentive Plan. The awards consist of options to purchase 19,031 shares and 23,332 restricted stock units (RSUs). The exercise price for options is set at $44.96, reflecting the stock's closing price on the grant date. Vesting for options will occur over four years, while RSUs will vest over four years as well, contingent on ongoing employment.
Apellis Pharmaceuticals (Nasdaq: APLS) announced its participation at the Bank of America Securities 2022 Healthcare Conference on May 11, 2022, at 8:40 a.m. PT. The event will feature a live webcast accessible through the company’s website, and a replay will be available for 30 days afterward.
As a leader in complement therapies, Apellis focuses on developing transformative treatments for diseases related to complement cascade activation across various fields, including hematology, ophthalmology, nephrology, and neurology.
Apellis Pharmaceuticals reported $12.1 million in U.S. net product revenues for EMPAVELI® (pegcetacoplan) in Q1 2022, with total revenues reaching $14.4 million. The company is on track to submit a New Drug Application (NDA) for pegcetacoplan in geographic atrophy by Q2 2022 and completed enrollment in a Phase 2 study for amyotrophic lateral sclerosis (ALS). Cash and investments totaled $965.3 million as of March 31, 2022, ensuring a runway into Q1 2024. Despite a net loss of $138.9 million, the firm is optimistic about its growth trajectory.
Apellis Pharmaceuticals (Nasdaq: APLS) has appointed Peter Hillmen, a prominent hematologist, as the head of hematology engagement, effective May 23, 2022. Hillmen brings decades of expertise in paroxysmal nocturnal hemoglobinuria (PNH), having developed treatments including EMPAVELI (pegcetacoplan). His role will focus on expanding collaborations with U.S. hematology leaders and enhancing Apellis' initiatives. EMPAVELI is positioned as a potential new standard of care for PNH, demonstrating superior effectiveness compared to existing therapies.
Apellis Pharmaceuticals (APLS) reported promising long-term results from the Phase 3 DERBY and OAKS studies for pegcetacoplan, a targeted C3 therapy, showing significant reductions in geographic atrophy (GA) lesion growth after 18 months.
Monthly and every-other-month treatments led to reductions of up to 33% for extrafoveal lesions and 19% for foveal lesions (p<0.0001). This positions pegcetacoplan as a potential first treatment for GA, a leading cause of blindness affecting over 5 million globally. Apellis plans to submit a New Drug Application to the FDA in Q2 2022.
Apellis Pharmaceuticals, a leader in complement medicine, will host a conference call and webcast on May 4, 2022, at 4:30 p.m. ET to discuss its first quarter 2022 financial results. The live call can be accessed by pre-registering online, and a replay will be available for 30 days. The company is committed to delivering transformative therapies for rare, retinal, and neurological diseases, highlighted by the launch of the first new class of complement medicine in 15 years with its targeted C3 therapy.
FAQ
What is the current stock price of Apellis Pharmace (APLS)?
What is the market cap of Apellis Pharmace (APLS)?
